aXichem AB (FRA:A6X)

Market Cap	16.40M -12.9%
Revenue (ttm)	1.72M +69.4%
Net Income	-1.33M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1970
Previous Close	0.1865
Day's Range	0.1970 - 0.1970
52-Week Range	0.0698 - 0.3230
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About aXichem AB

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. The company offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen, a solution for improved health for chickens, hens, pigs, and piglets. The company was founded in 1999 and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A6X

Financial Performance

In 2025, aXichem AB's revenue was 18.45 million, an increase of 115.24% compared to the previous year's 8.57 million. Losses were -17.63 million, -1.01% less than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 27, 2026

Data Sources Report a data error